| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786024 | Clinical Oncology | 2018 | 6 Pages |
Abstract
SBRT is safe in the treatment of high-risk, very high-risk and node-positive prostate cancer, even with prophylactic pelvic radiotherapy or prior transurethral resection of prostate. Longer follow-up is required to determine efficacy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
V. Murthy, M. Gupta, G. Mulye, S. Maulik, M. Munshi, R. Krishnatry, R. Phurailatpam, R. Mhatre, G. Prakash, G. Bakshi,